Heart muscle changes in facioscapulohumeral muscular dystrophy type 1 applying cardiac magnetic resonance

Cardiac involvement in facioscapulohumeral muscular dystrophy type 1 patients with preserved ejection fraction – assessment by cardiovascular magnetic resonance

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13744381

Enrollment

Registered

2017-07-25

Start date

2015-09-03

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facioscapulohumeral muscular dystrophy type 1 Nervous System Diseases Muscular dystrophy

Interventions

After inclusion, the study participants undergo a CMR. Furthermore, an age- and gender-matched healthy control group is identified. They receive the same CMR protocol. CMR is applied

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Genetically confirmed diagnosis of FSHD1 2. Age =18 years (no upper limit) 3. Age- and gender-matched healthy control group

Exclusion criteria

Exclusion criteria: Known vascular, cardiac diseases (e.g. coronary artery disease, significant valvular disease, myocarditis), malign diseases or known contraindications for CMR or Gadolinium- based contrast-media

Design outcomes

Primary

Measure	Time frame
Myocardial tissue injuries, detected using magnetic resonance imaging visually (qualitative) and quantitative including the presence and extent of lesions like fat and scar, measured at a single timepoint	—

Secondary

Measure	Time frame
Heart rhythm disturbances, assessed using ECG and ECG monitoring at a single timepoint	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 3, 2026